PROGRAM MENU
Educational Program

THSNA programming is focused on presenting the most current issues in Hemostasis and Thrombosis. The THSNA 2020 program will include on demand access to recorded talks covering four educational tracks as well as live panel discussion sessions, a nursing workshop, digital posters, corporate symposia, and a virtual exhibit hall with commercial booths.

Note that all timea are listed in Eastern Daylight Time (EDT) and any aspect of this program is subject to change.

  Tue - Oct 27      Wed - Oct 28      Thu - Oct 29      Fri - Oct 30   

WEDNESDAY, OCTOBER 28

10:00 - 11:30 AM
PLENARY SESSION
PLENARY 2: KEY PERSPECTIVES ON SAFE AND EFFECTIVE ANTICOAGULANT THERAPY
Chair/Organizer: Anne Rose, Christine Guelcher

This Plenary session will address what are widely viewed as the most important issues for safe and effective anticoagulation therapy. The session will include an expert overview of current and emerging anticoagulant therapies, the public health approach to ensuring anticoagulant medication safety, and issues to consider to minimize both thrombotic and bleeding complications for patients undergoing surgery.



ANTICOAGULANT TARGETS: OVERVIEW OF CURRENT AND EMERGING THERAPIES
Jeff Weitz. McMaster University


THE IMPORTANCE OF PATIENT SAFETY CONSIDERATIONS: ANTICOAGULANTS PLACE IN THE PUBLIC HEALTH APPROACH TO MEDICATION SAFETY
Charles (Kurt) Mahan.


MINIMIZING THROMBOTIC AND BLEEDING COMPLICATIONS IN THE SETTING OF SURGERY
PJ Devereaux. McMaster University

12:15 - 1:15 PM
SATELLITE SYMPOSIUM
CORPORATE LUNCH SYMPOSIUM: DOUBLE FEATURE: OBESITY IN HEMOPHILIA AND A TREATMENT OPTION FOR HEMOPHILIA A

Supported by: Novo Nordisk Pharmaceuticals, Inc.

The first part is an interactive program discussing the importance of managing obesity in the hemophilia community. Managing obesity is one of the toughest challenges for health care professionals in general and is often overlooked. This program will feature a discussion on obesity as a disease and how obesity impacts people with hemophilia. Results from a study designed to understand the barriers to initiating and maintaining weight loss in obese patients with hemophilia and to identify insights on the unique challenges of these patients from the perspective of health care professionals will be covered. In the second part, the program will feature aspects of the pathfinder clinical trial program and information on a factor VIII extended half-life product.



CORPORATE LUNCH SYMPOSIUM: HEMOPHILIA RESEARCH IN THE 21ST CENTURY

Sponsored By: Sanofi Genzyme

In this symposium, we will discuss a diverse range of possible approaches to managing hemophilia. We will reexamine what potential outcomes can be achieved for people with hemophilia and consider how we can support our patients on a path toward normalized hemostasis and quality of life.


2:00 - 3:30 PM
HEMOSTASIS / LABORATORY
EVALUATING FOR VON WILLEBRAND DISEASE
Chair/Organizer: William Nichols, Jemeel Abdulrehman


DIAGNOSTIC TESTING FOR VON WILLEBRAND DISEASE: TRENDS AND INSIGHTS FROM EXTERNAL QUALITY ASSESSMENTS OF NORTH AMERICAN LABORATORY PRACTICES
Jameel Abdulrehman. University Health Network


ASSESSMENT OF CHILDREN FOR VON WILLEBRAND DISEASE: NEW EVIDENCE ON HOW MANY TIMES WE NEED TO TEST
Bhavya Doshi. Children's Hospital of Philadelphia


GENETIC TESTING FOR VON WILLEBRAND DISEASE. UPDATE ON WHEN IT IS USEFUL
Veronica Flood. Medical College of Wisconsin

2:00 - 3:30 PM
BASIC SCIENCE
NEW INSIGHTS ON COAGULATION
Chair/Organizer: Kenneth Mann, Muriel Maurer


NEW INSIGHTS ON FACTOR XIII AND THROMBOSIS
Muriel Maurer. University of Louisville


ANTI-INFLAMMATORY EFFECTS OF FVIIA
LVM Rao. The University of Texas Health Science Center at Tyler


INITIATION OF BLOOD COAGULATION
James Morrissey. University of Michigan Medical School

2:00 - 3:30 PM
THROMBOSIS
THE CHANGING LANDSCAPE OF CANCER-ASSOCIATED VENOUS THROMBOEMBOLISM
Chair/Organizer: James Douketis , Crystal Watson


PRIMARY VTE PROPHYLAXIS IN CANCER PATIENTS
Marc Carrier. Ottawa Hospital Research Institute


TREATMENT OF CANCER-ASSOCIATED VTE, INCLUDING SPECIAL AND DIFFICULT PATIENT POPULATIONS.
Michael Streiff. Johns Hopkins University School of Medicine


CLINICAL CONTROVERSIES IN TREATING THROMBOSIS
Sam Schulman. McMaster University

4:15 - 5:45 PM
THROMBOSIS
DTI USE
Chair/Organizer: Luis Meillon, Teresa Bordeaux


DTI USE FOR ATYPICAL VTE (SPLANCHNIC BED, CEREBRAL VEIN THROMBOSIS) AND FOR HIT(T)
Rachel Rosovsky. Massachusetts General Hospital


DTI USE IN LVADS, ECMO, CARDIAC CATH
Jerrold Levy. Duke University School of Medicine


DTI USE IN PEDIATRICS
Shannon Carpenter. Children's Mercy Hospital

4:15 - 5:45 PM
HEMOSTASIS
EMERGING ISSUES IN BLEEDING DISORDERS
Chair/Organizer: Michelle Witkop, Shannon Jackson


GENETIC TESTING FOR CONGENITAL THROMBOCYTOPENIA SYNDROMES
Brian Branchford. University of Colorado School of Medicine and Children's Hospital Colorado


TREATING PAIN IN PATIENTS WITH BLEEDING DISORDERS
Tyler Buckner. University of Colorado School of Medicine


ANTICOAGULATION FOR PATIENTS WITH BLEEDING DISORDERS (COVERS VTE PROPHY IN ORTHO PROCEDURES, RX OF AF, CAD IN BLEEDING DISORDER PTS AND PVT IN CIRRHOTICS)
Craig Kessler.

4:15 - 5:45 PM
LABORATORY / BASIC SCIENCE
UPDATE ON THROMBOTIC MICROANGIOPATHIES
Chair/Organizer: Charles Eby, Marian Rollins Raval


OVERVIEW ON THROMBOTIC THROMBOCYTOPENIC PURPURA INCLUDING THE IMPORTANCE OF ADAMTS13 ASSAYS FOR DIAGNOSIS
Sateesh Chonat.


NEW INSIGHTS ON THE CONTRIBUTIONS OF ADAMTS13 AND COMPLEMENT TO TTP PATHOGENESIS FROM EXPERIMENTAL MODELS
X. Long Zheng. The University of Alabama at Birmingham


CLINICAL AND LABORATORY CONSIDERATIONS FOR THE LONG TERM FOLLOWUP AND TREATMENT OF TTP
James George. University of Oklahoma Health Sciences Center

6:00 - 7:00 PM
SATELLITE SYMPOSIUM
CORPORATE DINNER SYMPOSIUM: CLINICAL INSIGHTS IN VTE: RISK REDUCTION THROUGH PROPHYLAXIS & TREATMENT

Sponsored by: Janssen Pharmaceuticals, Inc.

Speaker: Samuel A. Berkman, MD, FACP
Clinical Professor of Medicine Division of Hematology-Oncology
UCLA Medical Center Beverly Hills, California

This lecture will discuss venous thromboembolism (VTE) prophylaxis, as well as treatment options for patients with deep vein thrombosis and/or pulmonary embolism, and how these treatment options may reduce the risk of recurrent thrombotic events.

Please read the full Prescribing Information, including Boxed WARNINGS for Xarelto, available at this event:
http://www. janssenlabels. com/package-insert/product-monograph/prescribing-information/XARELTO-pi. pdf


7:00 - 8:00 PM
SHORT TALKS
BASIC SCIENCE OF THROMBOSIS/ANTICOAGULATION


EXTRACELLULAR VESICLES DERIVED FROM RED BLOOD CELLS ACTIVATE MICROVASCULAR ENDOTHELIAL CELLS AND RESULT IN RED BLOOD CELL ADHESION IN SICKLE CELL DISEASE
Ran An1, Yuncheng Man1, Jane A. Little2, Umut A. Gurkan1. 1Case Western Reserve University, Cleveland, OH, USA. 2The University of North Carolina at Chapel Hill, Chapel Hill, NC, USA


COMBINATION OF HEPARIN AND A FX/FXA APTAMER TO REDUCE THROMBIN GENERATION IN MODELS OF CARDIOPULMONARY BYPASS
Charlene V. Chabata1, 2, James W. Frederiksen2, Ruwan Gunaratne3, Bruce A. Sullenger1, 2. 1Duke University, Department of Pharmacology and Cancer Biology, Durham, NC, USA. 2Duke University, Department of Surgery, Durham, NC, USA. 3Stanford University, School of Medicine, Palo Alto, CA, USA


DIFFERENTIAL NEUTRALIZATION OF APIXABAN, BETRIXABAN, EDOXABAN, AND RIVAROXABAN BY ANDEXANET ALFA AS MEASURED BY WHOLE BLOOD THROMBOELASTOGRAPHIC ANALYSIS
Siddharth Mehrotra1, Debra Hoppensteadt1, Walter Jeske1, Omer Iqbal1, Alfonso Tafur2, Bruce Lewis1, Jawed Fareed1. 1Loyola University Medical Center, Maywood, IL, USA. 2Northshore Health Systems, Skokie, IL, USA


INHIBITORS AGAINST PROCOAGULANT AND ANTIFIBRINOLYTIC PROPERTIES OF EXTRACELLULAR NUCLEIC ACIDS
Sreeparna Vappala1, 2, 8, Manu Thomas Kalathottukaren1, 2, 8, Srinivas Abbina1, 2, 8, Chanel La1, 3, 8, Libin Abraham4, 8, Iren Constantinescu1, 2, 8, Charles A Haynes1, 5, 8, Edward M Conway1, 6, 8, Jayachandran N Kizhakkedathu1, 2, 3, 7, 8. 1Centre for Blood Researc, Vancouver, BC, Canada. 2Department of Pathology and Laboratory medicine, Vancouver, BC, Canada. 3Department of Chemistry, Vancouver, BC, Canada. 4Microbiology and Immunology, Vancouver, BC, Canada. 5Chemical a Biological Engineering, Vancouver, BC, Canada. 6Department of Medicine, Vancouver, BC, Canada. 7The School of Biomedical Engineering, Vancouver, BC, Canada. 8University of British Columbia, Vancouver, BC, Canada


LABORATORY 2


BIOMARKERS OF INTRAVASCULAR COAGULATION AND FIBRINOLYSIS IN SEVERE SARS-COV-2 INFECTION (COVID-19)
Jansen N. Seheult1, 2, Michael P. Meyer2, Michelle N. Stram3, Andrea Cortese Hassett2, Alan Wells1, Haris Zia4, Alison Morris5, Janet S. Lee5, Bryan J. McVerry5, Matthew D. Neal6, Georgios Kitsios5, William Bain5. 1Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA. 2Vitalant Specialty Labs - Coag a MID, Pittsburgh, PA, USA. 3Department of Forensic Medicine, New York University, New York, NY, USA. 4Internal Medicine Residency Program, University of Pittsburgh Medical Center McKeesport, Pittsburgh, PA, USA. 5Division of Pulmonary, Allergy and Critical Care Medicine, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA. 6Pittsburgh Trauma Research Center and Department of Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA


ORDER SET MODIFICATION PROMOTES EFFECTIVE LABORATORY TEST UTILIZATION IN THE DIAGNOSIS OFHIT
Michael Kimbrell, John Larson, Mikhail Akbashev. Emory University Department of Medicine, Atlanta, GA, USA


UNRELIABILITY OF ACTIVATED PARTIAL THROMBOPLASTIN TIME TO MONITOR BIVALIRUDIN THERAPY IN PEDIATRIC EXTRACORPOREAL LIFE SUPPORT
Vadim Kostousov1, 2, Karen Bruzdoski1, Lisa Hensch1, 2, Shiu-Ki Rocky Hui1, 2, Jun Teruya1, 2. 1Texas Children's Hospital, Houston, TX, USA. 2Baylor College of Medicine, Houston, TX, USA


SEROTONIN RELEASE ASSAY BY LIQUID MASS SPECTROMETRY: A COMPARATIVE LABORATORY METHODS STUDY
Rachel R Leger1, Jennifer A Faber1, Deepti M Warad1, Ravinder J Singh1, Jansen N Seheult2, Rajiv K Pruthi1, Dong Chen1. 1Mayo Clinic, Rochester, MN, USA. 2University of Pittsburgh Medical Center, Pittsburgh, PA, USA


CHROMOGENIC BETHESDA ASSAY PERFORMANCE IN HEMOPHILIA A PATIENTS WITH AND WITHOUT EMICIZUMAB
Connie H Miller1, Brian Boylan1, Amanda B Payne1, Jennifer Driggers1, Christopher J Bean1, HIRS Investigators2. 1Centers for Disease Control and Prevention, Atlanta, GA, USA. 2See appendix, HIRS United States


PLATELETS AND VON WILLEBRAND FACTOR


ADVERSE BONE HEALTH AND WOUND HEALING OUTCOMES IN VON WILLEBRAND DISEASE
Divyaswathi Citla Sridhar1, 3, Yazan Abou-Ismail2, 3, Maria Pereda1, 3, Lalitha Nayak2, 3, Robert Sidonio Jr4, Sanjay Ahuja1, 3. 1Rainbow Babies a Children's Hospital, Cleveland, OH, USA. 2University Hospitals Cleveland Medical Center, Cleveland, OH, USA. 3Case Western Reserve University, Cleveland, OH, USA. 41Children, Atlanta, GA, USA


GENOTYPE VS PHENOTYPE:A CROSS-SECTIONAL STUDY EXAMINING THE INCIDENCE OF GENETIC VARIANTS IN PATIENTS WITH QUALITATIVE PLATELET DISORDERS
Kristina/M Haley, Stewart Worthington, Susan Lattimore, Mary Pat Bland, Jody Kujovich. Oregon Health a Science University, Portland, OR, USA


PLATELETS AS VERSATILE EFFECTORS OF THROMBOINFLAMMATION IN CHRONIC MYELOPROLIFERATIVE NEOPLASMS
Anandi Krishnan1, Wenfei Du2, Cecelia Perkins3, Zhu Shen4, Jason Gotlib5, James Zehnder6. 1Pathology, Stanford, CA, USA. 2Statistics, Stanford, CA, USA. 3Hematology, Stanford United States. 4Statistics, Stanford, CA, USA. 5Hematology, Stanford, CA, USA. 6Hematology, Stanford, CA, USA

7:00 - 7:45 PM
POSTER SESSION
POSTER SESSION 3


A1. ANTICOAGULATION CLINICS


1

EVALUATION OF THE VALIDITY OF SAME-TT2R2 SCORE IN A COHORT OF VENOUS THROMBOEMBOLISM PATIENTS TREATED WITH WARFARIN IN QATAR
Eman Alhmoud1, Mohammed Abdulgelil2, Walid Mekkawi2, Osama Abd El Samad1, Hazem Elewa3, Abdelnasser Elzouki 2. 1Al-Wakra Hospital, Doha, Qatar. 2Hamad General Hospital, Doha, Qatar. 3Qatar University-College of Pharmacy, Doha, Qatar


2

THE RELATIONSHIP BETWEEN MISSED APPOINTMENTS AND ANTICOAGULATION OUTCOMES IN AN INNER CITY, SOCIOECONOMICALLY DISADVANTAGED POPULATION: A PROSPECTIVE COHORT STUDY
Ali Alobaidi1, Crissel Marie Arban1, Connie H. Yan1, Sandra Walko1, Miranda Kopfman1, Maryam Naveed1, Lisa K. Sharp1, 2, Edith Nutescu1, 2. 1Department of Pharmacy Systems, Outcomes, and Policy, University of Illinois at Chicago, Chicago, IL, USA. 2Center for Pharmacoepidemiology a Pharmacoeconomic Research, University of Illinois at Chicago, Chicago, IL, USA


3

COMPARING THE EFFECTIVENESS AND SAFETY OF RESTARTING WARFARIN USING LOADING DOSES VERSUS MAINTENANCE DOSES FOLLOWING AN ELECTIVE DAY PROCEDURE: A RETROSPECTIVE STUDY
Joey J. Champigny, Jeff Nagge, Caitlin Carter. University of Waterloo, Kitchener, ON, Canada


4

CREATION OF A NEONATAL THROMBOSIS CENTER AND ITS USE TO SUCCESSFULLY TREAT INFANTS WITH SEVERE THROMBOSES
Elizabeth Gunn3, Shailly Gaur3, Matthew Saxonhouse2, 3, Ashley Hinson1, 3. 1Division of Cancer and Blood Disorders, Charlotte, NC, USA. 2Division of Neonatology, Charlotte, NC, USA. 3Department of Pediatrics, Levine Children's Hospital, Charlotte, NC, USA


5

IMPLEMENTATION OF A PROCESS IMPROVEMENT INITIATIVE OPTIMIZES THE MANAGEMENT OF VENOUS THROMBOEMBOLISM IN THE OUTPATIENT SETTING OF A COMMUNITY HEALTH CENTRE.
Christie Kim, Connie Vo. St. Joseph Health Centre, Toronto, ON, Canada


6

EFFECT OF POLYPHARMACY ON TIME IN THERAPEUTIC RANGE OF WARFARIN THERAPY IN PATIENTS WITH NONVALVULAR ATRIAL FIBRILLATION
Shaban Mohammed1, 4, Mohamed Kasem1, Amer Aljundi1, Mohammed Alhashemi2, Ayman El-Menyar3, 5, Osama Abd El Samad1, Moza Al Hail1, Nidal Asaad2. 1Pharmacy Department, Hamad Medical Corporation, Doha, Qatar. 2Heart Hospital, Hamad Medical Corporation, Doha, Qatar. 32Department of Clinical Medicine, Weill Cornel Medical College, Doha, Qatar. 4American University of Barbados School of Medicine, Barbados, Barbados, Barbados. 53Department of Surgery, Clinical Research, Hamad Medical Corporation, Doha, Qatar


7

EVALUATION OF A POPULATION-BASED MANAGEMENT TOOL IN IDENTIFYING POTENTIAL INTERACTIONS BETWEEN DIRECT ORAL ANTICOAGULANTS AND NON-STEROIDAL ANTI-INFLAMMATORY DRUGS AT A VETERANS AFFAIRS HEALTH CARE SYSTEM
Liem T. Nguyen, Rebecca F. Edwards, Jon E. Folstad, Juan D. Mobley, Jina W. Almond. Salisbury VA Health Care System, Salisbury, NC, USA


8

DRVV TESTING ON PATIENTS RECIEVING ANTICOAGULANT THERAPY
Maria Notini1, Dr. Thomas L Ortel2. 1Duke Health System, durham, NC, USA. 2Duke Health System, durham, NC, USA


9

A RETROSPECTIVE EVALUATION OF DIRECT ORAL ANTICOAGULANTS (DOACS) IN OBESE END STAGE RENAL DISEASE (ESRD) PATIENTS
Tanvi Patil1, Abraham B Gebremariam2, Alamdeep Kaur1. 1Veterans health Administration, Salem, VA, USA. 2Applachian University school of Pharmacy, Oakwood, VA, USA


10

OPERATIONAL MODEL OF A PERIOPERATIVE ANTICOAGULATION AND BRIDGING CLINIC: A CASE STUDY
Laurie A. Sardo1, 2, Noah H. Spencer1, James Douketis1, 3, Joanne P. Cordell4, Julia Bayadinova1. 1St. Joseph's Healthcare Hamilton, Hamilton, ON, Canada. 2Department of Nursing, McMaster University, Hamilton, ON, Canada. 3Department of Medicine, McMaster University, Hamilton, ON, Canada. 4Cordell Limited, Toronto, ON, Canada


11

COMPARABILITY OF POINT OF CARE VERSUS LABORATORY INR METHODS WITH VENOUS AND CAPILLARY SPECIMENS
Roona Sinha1, Nancy Hodgson2, Sibasis Daspal1, Matthew Bradshaw1, Lyon Martha1. 1University of Saskatchewan, Saskatoon, SK, Canada. 2Saskatchewan Health Authority, Saskatoon, SK, Canada


12

POINT-OF-CARE COAGULATION MONITORING USING A NOVEL OPTICAL SENSOR IN PATIENTS UNDERGOING CARDIAC SURGERY
Diane Malu Tshikudi1, 2, Alexandra G. Wirth1, 2, Michael N. Andrawes2, Seemantini K. Nadkarni1, 2, 3. 1Wellman Center for Photomedicine, Boston, MA, USA. 2Massachusetts General Hospital, Boston, MA, USA. 3Harvard Medical School, Boston, MA, USA


A2. PLATELET ACTIVATION AND BIOCHEMISTRY


13

UTILIZATION OF THROMBOELASTOGRAPHY WITH PLATELET MAPPING TO GUIDE PERIOPERATIVE MANAGEMENT OF INTRAVENOUS IMMUNOGLOBULIN, STEROIDS, AND BLOOD COMPONENT THERAPY IN A PATIENT WITH IDIOPATHIC THROMBOCYTOPENIA PURPURA REQUIRING EMERGENCY CORONARY ARTERY BYPASS GRAFTING.
Mark Walsh, MD1, Jordan Hatch, BS2, Hau C Kwaan, MD3, Faran Bokhari, MD, FACS4, Scott Thomas, MD5, Gina Arsenault, MT (ASCP), MSA5, Gerald Rinon, MT (ASCP)5, Robert March, MD1, Christopher Trumpower, CCP1, Rolan Pascual, MD6, Ashfaq Turk, MD1, Shareen Lee, MS1. 1St. Joseph Regional Medical Center, Mishawaka, IN, USA. 2Indiana University School of Medicine, South Bend, IN, USA. 3Division of Hematology-Oncology, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA. 4John H. Stroger, Jr. Hospital, Chicago, IL, USA. 5Beacon Health Systems, South Bend, IN, USA. 6Michiana Hematology and Oncology, Mishawaka, IN, USA


A5. BLOOD COAGULATION AND FIBRINOLYTIC FACTORS


0

UNRAVELLING THE ROLE OF THE FACTOR X GLA DOMAIN IN INITIATION OF THE CLOTTING CASCADE
Divyani Paul1, James Morrissey1, 2. 1Department of Biological Chemistry, Ann Arbor, MI, USA. 2Department of Internal Medicine, Ann Arbor, MI, USA


A6. DISORDERS OF COAGULATION OR FIBRINOLYSIS


14

IMPLEMENTING GOAL-HēM, A GOAL ATTAINMENT SCALING INSTRUMENT
Justin Stanley1, Taylor Dunn1, Jorge Caicedo2, Michael Denne2, Jonathan Roberts3, Kenneth Rockwood1, 4. 1DGI Clinical Inc, Halifax, NS, Canada. 2Baxalta US Inc, a Takeda company, Cambridge, MA, USA. 3Bleeding a Clotting Disorders Institute, Peoria, IL, USA. 4Dalhousie University, Halifax, NS, Canada


15

EFFICACY AND SAFETY RESULTS FROM A PHASE 3, RANDOMIZED, MULTICENTER STUDY OF RURIOCTOCOG ALFA PEGOL PHARMACOKINETIC-GUIDED PROPHYLAXIS TARGETING TWO FACTOR VIII TROUGH LEVELS IN PATIENTS WITH SEVERE HEMOPHILIA A (PROPEL STUDY): A CONSIDERATION FOR PERSONALIZED PROPHYLAXIS
Vlad C. Radulescu1, Robert Klamroth2, Jerzy Windyga3, Peter Collins4, Oleksandra Stasyshyn5, Hishamshah M. Ibrahim6, Werner Engl7, Srilatha D. Tangada8, Bruce Ewenstein8. 1University of Kentucky, Kentucky Children, Lexington, KY, USA. 2Vivantes Klinikum im Friedrichshain, Berlin Germany. 3Institute of Hematology and Transfusion Medicine, Warsaw, Poland. 4School of Medicine, Cardiff University, Cardiff, United Kingdom. 5Academy of Medical Sciences of Ukraine, Lviv, Ukrenia. 6Hospital Kuala Lumpur, Kuala Lumpur, Malaysia. 7Baxalta Innovations GmbH, a Takeda company, Vienna, Austria. 8Baxalta US Inc, a Takeda company, Cambridge, MA, USA


16

COMPARISON OF HEXAGONAL PHASE PHOSPHOLIPID NEUTRALIZATION ASSAYS FOR LUPUS ANTICOAGULANT DETECTION
Colin Douglas, Rachel Clarke, Navya Kesavan, Derek Lamont, Ali Sadeghi-Khomami, Amanda Wood, Karen Black. Precision BioLogic Inc, Dartmouth, NS, Canada


17

EXTERNAL QUALIFICATION OF THE WEB-ACCESSIBLE POPULATION PHARMACOKINETIC SERVICE - HEMOPHILIA (WAPPS-HEMO) MODELS FOR OCTOCOG ALFA (KOVALTRY) USING REAL PATIENT DATA
Pierre Chelle1, Dagmar Hajducek1, Mohammed Mahdi2, Stuart Young2, Alfonso Iorio3, Andrea Edginton1. 1School of Pharmacy, University of Waterloo, Waterloo, Canada. 2Bayer, Mississauga, Canada. 3McMaster-Bayer Endowed Research Chair for Clinical Epidemiology of Congenital Bleeding Disorders, Department of Medicine, Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, Canada


18

DERMATOGLYPHIC TRAIT ASYMMETRY: A PREDICTING TOOL FOR SCREENING HEMOPHILIC PATIENTS IN GUYANA.
Ameet K. Jha1, Daniel J. Kanhai1, Michael Chapp3, Sujatha D'costa2. 1Texila American University, East Bank Demerara, Guyana. 2American University of Antigua, St. Johns, Antigua & Barbuda. 3Georgetown Public Hospital Corporation, Georgetown, Guyana


19

HEMOSTASIOLOGICAL INDICATORS FOR DIAGNOSING PREECLAMPSIA IN PREGNANT WOMEN.
Bakhodir Kurbanov. Tashkent Pediatric Medical Institute, Tashkent, Uzbekistan


20

RAPID DESENSITIZATION AND SUBSEQUENT IMMUNE TOLERANCE INDUCTION IN A PATIENT WITH HYPERSENSITIVITY AND INHIBITOR TO FACTOR VIII
William B Mitchell. Children's Hospital at Montefiore, Bronx, NY, USA


A8. ANTITHROMBOTIC THERAPY


0

COMPARISON OF PERCENT ADJUSTED AND PREDEFINED INCREMENTAL ADJUSTED ARGATROBAN DOSING NOMOGRAMS: MORE FREQUENT MONITORING DOES NOT IMPROVE TIME TO THERAPEUTIC ANTICOAGULATION
Mark E. Jao, Eric R. Wenzler, Keri S. Kim. University of Illinois at Chicago, Chicago, IL, USA


A9. INFORMATIONAL ABSTRACT (POSTER ONLY)


0

COVID-19 CONCERNS IN THE UNITED STATES (US) BLEEDING DISORDERS COMMUNITY
Maria E Santaella, RN-BC, MSN, CPHON, Cynthia Nichols, PhD, Michelle Witkop, DNP, FNP-BC. National Hemophilia Foundation, New York, NY, USA


21

PRELIMINARY VALIDATION OF A QUANTITATIVE HUMAN D-DIMER TEST ON A NOVEL HAND HELD LAB-ON-A-CHIP PLATFORM
Nahla M Heikal1, Melissa Stuart1, Wei Wang2, Shanghsuan Lin2, Xiyn Chen2, Robert McBane1, 3. 1Mayo Clinic. Laboratory Medicine and Pathology, Rochester, MN, USA. 2Zepto life technology, St. Paul, MN, USA. 3Mayo Clinic. Department of Medicine, Rochester, MN, USA


22

RISK OF THROMBOVASCULAR EVENTS IS INCREASED IN INDIVIDUALS WITH PREVALENT AUTOIMMUNE DISEASES: FINDINGS FROM A RAPID EVIDENCE REVIEW
Juliana Setyawan1, Nila Sathe2, Chris Rabbat1. 1Arena Pharmaceuticals, San Diego, CA, USA. 2Premier, Inc, Charlotte, NC, USA


23

CHARACTERISTICS EVALUATED FOR POTENTIAL ASSOCIATION WITH THROMBOVASCULAR EVENT RISK IN PATIENTS WITH PREVALENT AUTOIMMUNE CONDITIONS: FINDINGS FROM A RAPID EVIDENCE REVIEW
Nila Sathe1, Chris Rabbat2, Juliana Setyawan2. 1Premier, Inc, Charlotte, NC, USA. 2Arena Pharmaceuticals, San Diego, CA, USA


POSTER SESSION 4


A3. VASCULAR WALL BIOLOGY, ENDOTHELIAL PROGENITOR CELLS AND PLATELET ADHESION


24

COLLAGEN TURNOVER MARKERS IN HEMOPHILIA
Hira Latif1, Syed W Haider1, Craig M Kessler2. 1MedStar Washington Hospital Center, Washington, DC, USA. 2MedStar Georgetown University Hospital, Washington, DC, USA


A4. DISORDERS OF PLATELET NUMBER OR FUNCTION


25

REACTIVE THROMBOCYTOSIS IN PEDIATRIC POPULATION: ANALYSIS OF INDOOR PATIENTS IN A TERTIARY CARE HOSPITAL
Asma N Cheema1, Zulfiqar A Rana2, Zille Rubab1. 1Department of Pathology, Children's Hospital a The Institute of Child Health, Multan, Pakistan. 2Department of Hematology a Oncology, Children's Hospital a The Institute of Child Health, Multan, Pakistan


26

SUCCESSFUL PERIPARTUM MANAGEMENT IN BERNARD SOULIER SYNDROME WITH SEVERE THROMBOCYTOPENIA AND A PREVIOUSLY UNREPORTED GP1BA PATHOLOGIC VARIANT.
Colleen Ciccosanti1, Claire Philipp2. 1Rutgers Robert Wood Johnson Medical School, Department of Medicine, New Brunswick, NJ, USA. 2Rutgers Robert Wood Johnson Medical School, Department of Hematology, New Brunswick, NJ, USA


27

HEPATIC DISORDERS CONTRIBUTE TO PLATELET DYSFUNCTION
Ambar Farooqui, Cassandra Bacher, Fakiha Siddiqui, Bharathi Darvath, Debra Hoppensteadt, Omer Iqbal, Jawed Fareed, Magdalena George, David VanThiel. Loyola University Medical Center, Maywood, IL, USA


28

EVALUATION OF ANTICOAGULATION PRESCRIBING PATTERNS IN PATIENTS WITH SUSPECTED OR CONFIRMED HEPARIN-INDUCED THROMBOCYTOPENIA
Jona Lekura, Ashley Semma, Mya Tran, Ahlam Almansoub, Klarita Seitllari, Philip Kuriakose. Henry Ford Health System, Detroit, MI, USA


29

ANALYSIS OF HEPARIN-INDUCED THROMBOCYTOPENIA (HIT) TESTING AND IMPLEMENTATION OF ELECTRONIC RECORD BASED CALCULATION OF 4T SCORE
Hannah L McRae1, Rialnat Lawal2, Mofiyin Obadina2, Frank Akwaa3, Majed Refaai1, 3. 1Department of Pathology and Laboratory Medicine, University of Rochester Medical Center, Rochester, NY, USA. 2Department of Medicine, University of Rochester Medical Center, Rochester, NY, USA. 3Department of Medicine, Division of Hematology/Oncology, Rochester, NY, USA


30

CLINICAL APPLICATION OF THE 4TS SCORE AND PLATELET COUNT TRENDS IN PATIENTS ON EXTRACORPOREAL MEMBRANE OXYGENATION WITH HEPARIN-INDUCED THROMBOCYTOPENIA - A SINGLE INSTITUTION STUDY
Anil K. Rengan1, Daniel Stapor1, Mark Weiner1, Hauqing Zhao1, Nadia Ali2. 1Lewis Katz School of Medicine at Temple University, Philadelphia, PA, USA. 2Department of Hematology at Temple University Hospital, Philadelphia, PA, USA


31

COMPARISON OF TWO DIFFERENT ELISA METHODS FOR HEPARIN-INDUCED THROMBOCYTOPENIA (HIT) SCREENING ON AN AUTOMATED ELISA PLATFORM
Paul W Riley, John G Chromczak. Diagnostica Stago, Inc, Parsippany, NJ, USA


32

WHOLE BLOOD IMPENDENCE AGGREGOMETRY AS A SCREEN FOR PLATELET DENSE GRANULE DEFICIENCY
Marian A. Rollins-Raval, Jay S. Raval, Richard A. Marlar. University of New Mexico, Albuquerque, NM, USA


33

PLATELET REFRACTORINESS AND THE ROLE OF LEUCODEPLETION BEFORE BONE MARROW TRANSPLANTATION IN SICKLE CELL DISEASE PATIENTS
Ambreen Sheikh. Dow University, Karachi Pakistan


34

LASER SPECKLE AGGREGOMETRY: A NOVEL TECHNIQUE FOR MONITORING PLATELETS FUNCTION
Diane M. Tshikudi1, 2, Asael Papour1, 2, Xin Liang1, 2, John Barranco1, Michael N. Andrawes1, Seemantini K. Nadkarni1, 2, 3. 1Wellman Center for Photomedicine, Boston, MA, USA. 2Massachusetts General Hospital, Boston, MA, USA. 3Harvard Medical School, Boston, MA, USA


A6. DISORDERS OF COAGULATION OR FIBRINOLYSIS


35

RISK FACTORS AMONG OUTPATIENTS AND HOSPITALIZED PATIENTS WITH VTE USING POPULATION-BASED SURVEILLANCE DATA FROM TWO US COUNTIES 2012-2014
Karon Abe1, Alys Adamski1, Aaron Wendleboe2, Nimia Reyes1, Gary Raskob2, Thomas Ortel3. 1Division of Blood Disorders, National Center on Birth Defects and Developmental Disabilities, Centers for Disease Control and Prevention, Atlanta, GA, USA. 2Hudson College of Public Health, University of Oklahoma Health Sciences, Norman, OK, USA. 3Division of Hematology, Duke University Medical Center Durham, NC, USA


36

VENOUS THROMBOEMBOLISM IN MELANOMA PATIENTS: ANALYSIS FROM THE NATIONAL INPATIENT SAMPLE DATABASE
Hussam Alhasson1, Anas Saad 2, Yu Zhao1, Zimu Gong 3, Muneer Alhusseini4. 1Rochester Regional Health/ Unity Hospital, Rochester, NY, USA. 2Cleveland Clinic Foundation, Cleveland, OH, USA. 3AMITA Health St Joseph Hospital, Chicago, IL, USA. 4Ascension St John Hospital, Detroit, MI, USA


37

VALIDATION OF CHROMOGENIC FACTOR VIII ACTIVITY ASSAYS AT CHILDREN'S HOSPITAL LOS ANGELES (CHLA)
Joshua M. Brown, PhD1, Melissa Arevalo1, Desiree Tan-Castillo1, Edward Leung, PhD, DABCC, FAACC1, 2, Guy Young, MD1, 2, Maurice O'Gorman, MBA, MSc, PhD, D(ABMLI)1, 2. 1Children's Hospital Los Angeles, Los Angeles, CA, USA. 2University of Southern California Keck School of Medicine, Los Angeles, CA, USA


38

EFFICACY OF UPFRONT LOW DOSE COMBINED IMMUNOSUPPRESSION IN ACQUIRED HEMOPHILIA A: A SINGLE CENTER RETROSPECTIVE COHORT STUDY
Lorraine A. Cafuir, Duc Q. Tran, Anthony DeBalsi, Christine L. Kempton. Emory University, Atlanta, GA, USA


39

SURGICAL SPLENECTOMY AND RISK OF VENOUS THROMBOEMBOLISM IN SICKLE CELL DISEASE
Jennifer Chen1, Manuela Plazas Montana2, Elizabeth Williams2, Payal Desai3, Joshua Field4, Sophie Lanzkron2, Jane Little5, Deepa Manwani6, Lynne Neumayer7, Rakhi P. Naik 2. 1The Johns Hopkins School of Medicine, Baltimore, MD, USA. 2Department of Hematology, Department of Medicine, Johns Hopkins University, Baltimore, MD, USA. 3The Ohio State University, Columbus, OH, USA. 4Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, USA. 5Department of Hematology and Oncology, School of Medicine, Case Western Reserve University, Cleveland, OH, USA. 6Department of Pediatrics, Albert Einstein College of Medicine, New York City, NY, USA. 7Department of Hematology Oncology, UCSF Benioff Children's Hospital and Research Center Oakland, Oakland, CA, USA


40

ASSESSMENT OF JOINT HEALTH USING POINT-OF-CARE ULTRASOUND IN WOMEN WITH BLEEDING DISORDERS
Kelli A Fraga, Rachel S Leeman, Joanna A Davis, Fernando F Corrales-Medina. University of Miami - Hemophilia Treatment Center, Miami, FL, USA


41

THROMBOSIS AND TRANSIENT ACQUIRED THROMBOPHILIA TRIGGERED BY EPSTEIN-BARR VIRUS IN PEDIATRICS
Jessica Garcia1, 2, Ayesha Zia1, 2. 1University of Texas Southwestern, Dallas, TX, USA. 2Children's Medical Center, Dallas, TX, USA


42

DIGITAL MONITORING OF SERIOUS ADVERSE EVENTS SIGNALS IN PATIENTS WITH BLEEDING DISORDERS
Marc Lara1, Michael Callaghan2, Meera Chitlur2, Suchitra Acharya3, Joseph Stanco3, Guy Young4, Robert Sidonio5, Maissaa Janbain6, Amina Rafique6, Angela Kellum6, Cindy Leissinger6. 1MicroHealt, Inc, NY, NY, USA. 2Children's Hospital of Michigan, Detroit, MI, USA. 3Northwell Health, New Hydde Park, NY, USA. 4Children's Hospital of Los Angeles, Los Angeles, CA, USA. 5Children's Healthcare of Atlanta, Atlanta, GA, USA. 6Tulane University School of Medicine, New Orleans, LA, USA


43

BLEEDING PREDICTIONS FOR PATIENTS WITH HEMOPHILIA A USING MACHINE LEARNING.
Marc Lara1, Marcela Barrios2, Angela Kellum3, Jonathan Elliott2, Milena Almagro2. 1MicroHealth, Inc, New York, NY, USA. 2New York University. Department of Economics, New York, NY, USA. 3Tulane University School of Medicine, New Orleans, LA, USA


44

DETERMINING PATHOGENICITY OF NOVEL VARIANTS FOUND IN BLEEDING/CLOTTING/PLATELET DISORDERS
Jihyun Moon, Jooeun Lim, Gayatri Raghuraman, Violet Votin, Bjorn Stromsness, James Kain, Mike Ero. Machaon Diagnostics, Inc, Oakland, CA, USA


A8. ANTITHROMBOTIC THERAPY


0

EVALUATION OF ANTICOAGULATION REGIMENS IN PATIENTS WITH COVID-19
Leila Forouzan, Alyssa Pagliaro, Veronika Colomy, Robert Wright, Travis Reinaker, John Knorr. Einstein Medical Center Philadelphia, Philadelphia, PA, USA


A9. INFORMATIONAL ABSTRACT (POSTER ONLY)


0

DEMOGRAPHIC DISTRIBUTION, CLINICAL PHYSIOGNOMICS AND THERAPEUTIC TRIALS OF COVID-19 IN PAKISTANI POPULATION
Asma Naseer Cheema1, 2, Aneeqa Hayat1, Muhammad Younas2, Azra 3, Rubya Khanum4. 1Department of Pathology, Children's Hospital a The Institute of Child Health, Multan Pakistan. 2Department of Pathology, CMH Multan, National University of Medical Sciences, Rawalpindi Pakistan. 3Department of Microbiology, Khyber Medical University, Peshawar Pakistan. 4Department of Pathology, University Medical a Dental College, The University of Faisalabad, Faisalabad Pakistan


0

ANTIBODY RESPONSE AGAINST COVID-19 AMONG HEALTHCARE WORKERS
Muhammad Younas1, Kamran Afzal1, Asma Khan1, Hamid Iqbal1, Kainat Younas3, Asma Naseer Cheema1, 2. 1CMH Multan, National University of Medical Sciences, Multan Pakistan. 2Children's Hospital a The Institute of Child Health, Multan Pakistan. 3Rawalpindi Medical University, Rawalpindi Pakistan


45

THE CONTRIBUTION OF CELL POPULATION DATA (CPD) COMPARED TO THE CONCENTRATION OF C-REACTIVE PROTEIN IN HOSPITALIZED PATIENTS IN SURGICAL RESUSCITATION IN UNIVERSITY HOSPITAL IBN ROCHD OF CASABLANCA-MOROCCO
Anass JARMOUMI1, Salma HASNANE1, Hanaa BENCHAREF1, Houcine BARROU2, Bouchra OUKKACHE1. 1Hematology laboratory of University Hospital Ibn Rochd, Casablanca, Morocco. 2Surgical resuscitation in University Hospital Ibn Rochd, Casablanca, Morocco


46

CLINICAL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF WILATE DURING PROPHYLAXIS IN PREVIOUSLY TREATED PATIENTS WITH VON WILLEBRAND DISEASE (VWD)
Bruce A Schwartz1, Robert Sidonio2. 1Octapharma, Hoboken, NJ, USA. 22Hemophilia of Georgia Center for Bleeding a Clotting Disorders, Atlanta, GA, USA

7:00 - 8:00 PM
SHORT TALKS
THROMBOSIS: RISKS


REDUCED CALF MUSCLE PUMP FUNCTION IS A RISK FACTOR FOR VENOUS THROMBOEMBOLISM AND MORTALITY
Damon / E Houghton, Aneel Ashrani, David Liedl, Ramila Mehta, Paul Wennberg, Waldemar Wysokinski, Thom Rooke, Robert McBane. Mayo Clinic, Rochester, MN, USA


INCREASED RISK OF THROMBOSIS IN ALK-REARRANGED LUNG CANCER
Hanny Al-Samkari1, 2, Orly Leiva2, 3, Ibiayi Dagogo-Jack1, 2, Alice Shaw1, 2, Pavan K. Bendapudi1, 2, Jean M. Connors2, 4. 1Division of Hematology Oncology, Massachusetts General Hospital, Boston, MA, USA. 2Harvard Medical School, Boston, MA, USA. 3Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA. 4Hematology Division, Brigham and Women's Hospital, Boston, MA, USA


EFFECT OF RACE/ETHNICITY ON THE RISK OF CANCER-ASSOCIATED VENOUS THROMBOEMBOLISM FOR THREE COMMON CANCERS
Tatini Datta, Ann Brunson, Anjlee Mahajan, Theresa Keegan, Ted Wun. Center for Oncology Hematology Outcomes Research and Training (COHORT), Division of Hematology and Oncology, University of California Davis School of Medicine, Sacramento, CA, USA


LOW BLEEDING RISK PROCEDURES: SHOULD WE LET DOAC BE?
Muhammad A. Sheikh1, Xiaowen Kong2, Brian Haymart2, Xiaokui Gu2, Scott Kaatz3, Gregory Krol3, Jay Kozlowski4, Musa Dahu5, Mona Ali6, Steven Almany7, Eva Kline-Rogers2, James Froehlich2, Geoffrey D. Barnes2. 1Division of Hospital Medicine, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA. 2Division of Cardiovascular Medicine, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA. 3Department of Internal Medicine, Henry Ford Hospital, Detroit, MI, USA. 4Department of Cardiovascular Medicine, Huron Valley Sinai Hospital, Commerce Township, MI, USA. 5Heart and Vascular Institute, Spectrum Health System, Grand Rapids, MI, USA. 6Department of Pharmacy, Beaumont Hospital, Royal Oak, MI, USA. 7Department of Internal Medicine, Beaumont Health, Oakland University School of Medicine, Royal Oak, MI, USA


CREATION OF A REAL-TIME RISK PREDICTION MODEL FOR PEDIATRIC THROMBOSIS EVENTS
Shannon C. Walker1, C. Buddy Creech1, Henry J. Domenico2, Daniel W. Byrne2, Allison P. Wheeler1, 2. 1Monroe Carell Jr. Children's Hospital at Vanderbilt, Nashville, TN, USA. 2Vanderbilt University Medical Center, Nashville, TN, USA